Recently, Salubris announced that the phase 3 clinical trial of S086 tablets (program code: SAL086) for the treatment of mild to moderate primary hypertension has been completed with unblinding and statistical data analysis, and the preliminary results showed that the primary endpoint was achieved.
This clinical trial was a randomized, double-blind, positive drug parallel control, and multi-center phase 3 clinical study. So far, 1197 patients have been enrolled in this trial. All subjects had completed the double-blind treatment, and the results of the preliminary statistical analysis after unblinding showed that the primary endpoint was met, suggesting that the antihypertensive effect of S086 tablets was significant and dose-dependent, meanwhile the overall safety of S086 tablets was good.
After the product is launched, it will further enrich the innovative product pipeline of Salubris in the cardiovascular area, meet the unmet clinical needs, and enhance the comprehensive competitiveness of Salubris in the field of chronic diseases.
